Roivant Sciences Stock Analysis
| ROIV Stock | USD 27.48 0.39 1.44% |
IPO Date 1st of October 2021 | 200 Day MA 16.1 | 50 Day MA 22.6172 | Beta 1.233 |
Roivant Sciences holds a debt-to-equity ratio of 0.275. At this time, Roivant Sciences' Short Term Debt is fairly stable compared to the past year. Short and Long Term Debt is likely to climb to about 21.1 M in 2026, whereas Net Debt is likely to drop (2.5 B) in 2026. Roivant Sciences' financial risk is the risk to Roivant Sciences stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Roivant Sciences' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Roivant Sciences' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Roivant Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Roivant Sciences' stakeholders.
For many companies, including Roivant Sciences, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Roivant Sciences, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Roivant Sciences' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 4.5406 | Enterprise Value Ebitda 0.7433 | Price Sales 1.5 K | Shares Float 500.6 M | Wall Street Target Price 31.7273 |
Roivant Sciences is undervalued with Real Value of 31.0 and Target Price of 31.73. The main objective of Roivant Sciences stock analysis is to determine its intrinsic value, which is an estimate of what Roivant Sciences is worth, separate from its market price. There are two main types of Roivant Sciences' stock analysis: fundamental analysis and technical analysis.
The Roivant Sciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Roivant Sciences is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Roivant Stock trading window is adjusted to America/New York timezone.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roivant Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. Roivant Stock Analysis Notes
About 25.0% of the company outstanding shares are owned by corporate insiders. The book value of Roivant Sciences was at this time reported as 6.02. The company recorded a loss per share of 1.17. Roivant Sciences had not issued any dividends in recent years. Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company was founded in 2014 and is based in London, the United Kingdom. Roivant Sciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 863 people. To find out more about Roivant Sciences contact Matthew Gline at 44 20 7400 3347 or learn more at https://roivant.com.Roivant Sciences Quarterly Total Revenue |
|
Roivant Sciences Investment Alerts
| Roivant Sciences appears to be risky and price may revert if volatility continues | |
| Roivant Sciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 29.05 M. Net Loss for the year was (356.73 M) with loss before overhead, payroll, taxes, and interest of (614.67 M). | |
| Roivant Sciences currently holds about 1.94 B in cash with (839.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76. | |
| Roivant Sciences has a poor financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Disposition of 425000 shares by Qvt Financial Lp of Roivant Sciences at 26.67 subject to Rule 16b-3 |
Roivant Largest EPS Surprises
Earnings surprises can significantly impact Roivant Sciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-05-29 | 2025-03-31 | -0.2629 | -0.29 | -0.0271 | 10 | ||
2025-02-11 | 2024-12-31 | -0.24 | -0.1988 | 0.0412 | 17 | ||
2022-06-28 | 2022-03-31 | -0.32 | -0.27 | 0.05 | 15 |
Roivant Sciences Environmental, Social, and Governance (ESG) Scores
Roivant Sciences' ESG score is a quantitative measure that evaluates Roivant Sciences' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Roivant Sciences' operations that may have significant financial implications and affect Roivant Sciences' stock price as well as guide investors towards more socially responsible investments.
Roivant Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2025-06-30 | 7.9 M | Geode Capital Management, Llc | 2025-06-30 | 7.8 M | Ubs Group Ag | 2025-06-30 | 5.1 M | Anchorage Advisors, Llc | 2025-06-30 | 4.8 M | Blackbarn Capital Partners Lp | 2025-06-30 | 4.6 M | Bank Of New York Mellon Corp | 2025-06-30 | 4.5 M | Woodline Partners Lp | 2025-06-30 | 4 M | Whitefort Capital Management, Lp. | 2025-06-30 | 3.9 M | Baker Bros Advisors Lp | 2025-06-30 | 3.8 M | Sb Investment Advisers (uk) Ltd | 2025-06-30 | 60 M | Fmr Inc | 2025-06-30 | 55.5 M |
Roivant Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 19.39 B.Roivant Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.17) | (0.18) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.04) | (0.04) |
Management Efficiency
Roivant Sciences has return on total asset (ROA) of (0.1447) % which means that it has lost $0.1447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1914) %, meaning that it created substantial loss on money invested by shareholders. Roivant Sciences' management efficiency ratios could be used to measure how well Roivant Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.03 in 2026. Return On Capital Employed is likely to drop to -0.18 in 2026. At this time, Roivant Sciences' Net Tangible Assets are fairly stable compared to the past year. Other Assets is likely to climb to about 46.2 M in 2026, whereas Non Current Assets Total are likely to drop slightly above 458.9 M in 2026.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.44 | 3.59 | |
| Tangible Book Value Per Share | 6.44 | 3.54 | |
| Enterprise Value Over EBITDA | (3.85) | (4.04) | |
| Price Book Value Ratio | 1.80 | 3.03 | |
| Enterprise Value Multiple | (3.85) | (4.04) | |
| Price Fair Value | 1.80 | 3.03 | |
| Enterprise Value | 2.5 B | 3.9 B |
The operational strategies employed by Roivant Sciences management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Technical Drivers
As of the 19th of February, Roivant Sciences holds the Semi Deviation of 1.41, coefficient of variation of 789.51, and Risk Adjusted Performance of 0.108. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Roivant Sciences, as well as the relationship between them. Please check Roivant Sciences coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Roivant Sciences is priced some-what accurately, providing market reflects its current price of 27.48 per share. Given that Roivant Sciences has jensen alpha of 0.3649, we recommend you to check out Roivant Sciences's recent market performance to make sure the company can sustain itself at a future point.Roivant Sciences Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two.
Roivant Sciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Roivant Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Roivant Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Roivant Sciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Roivant Sciences Outstanding Bonds
Roivant Sciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Roivant Sciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Roivant bonds can be classified according to their maturity, which is the date when Roivant Sciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Roivant Sciences Predictive Daily Indicators
Roivant Sciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Roivant Sciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Roivant Sciences Corporate Filings
F4 | 18th of February 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 17th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 13th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 11th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
8K | 6th of February 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 5th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 22nd of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 14th of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Roivant Sciences Forecast Models
Roivant Sciences' time-series forecasting models are one of many Roivant Sciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Roivant Sciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Roivant Sciences Bond Ratings
Roivant Sciences financial ratings play a critical role in determining how much Roivant Sciences have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Roivant Sciences' borrowing costs.| Piotroski F Score | 4 | Poor | View |
| Beneish M Score | (2.47) | Unlikely Manipulator | View |
Roivant Sciences Debt to Cash Allocation
Many companies such as Roivant Sciences, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Roivant Sciences currently holds 100.17 M in liabilities with Debt to Equity (D/E) ratio of 0.28, which may suggest the company is not taking enough advantage from borrowing. Roivant Sciences has a current ratio of 6.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Roivant Sciences' use of debt, we should always consider it together with its cash and equity.Roivant Sciences Total Assets Over Time
Roivant Sciences Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Roivant Sciences uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Roivant Sciences Debt Ratio | 2.01 |
Roivant Sciences Corporate Bonds Issued
Roivant Short Long Term Debt Total
Short Long Term Debt Total |
|
About Roivant Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Roivant Sciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Roivant shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Roivant Sciences. By using and applying Roivant Stock analysis, traders can create a robust methodology for identifying Roivant entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (21.11) | (20.06) | |
| Operating Profit Margin | (31.08) | (29.53) | |
| Net Loss | (5.33) | (5.06) | |
| Gross Profit Margin | 1.11 | 1.00 |
Current Roivant Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Roivant analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Roivant analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 31.73 | Strong Buy | 10 | Odds |
Most Roivant analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Roivant stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Roivant Sciences, talking to its executives and customers, or listening to Roivant conference calls.
Roivant Stock Analysis Indicators
Roivant Sciences stock analysis indicators help investors evaluate how Roivant Sciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Roivant Sciences shares will generate the highest return on investment. By understating and applying Roivant Sciences stock analysis, traders can identify Roivant Sciences position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 6.6 B | |
| Common Stock Shares Outstanding | 725.4 M | |
| Total Stockholder Equity | 4.7 B | |
| Total Cashflows From Investing Activities | -1.8 B | |
| Tax Provision | 48.2 M | |
| Quarterly Earnings Growth Y O Y | -0.961 | |
| Property Plant And Equipment Net | 101.1 M | |
| Cash And Short Term Investments | 4.9 B | |
| Cash | 2.7 B | |
| Accounts Payable | 23.7 M | |
| Net Debt | -2.6 B | |
| 50 Day M A | 22.6172 | |
| Total Current Liabilities | 149.4 M | |
| Other Operating Expenses | 1 B | |
| Non Current Assets Total | 436.9 M | |
| Non Currrent Assets Other | 32.9 M | |
| Stock Based Compensation | 289 M |
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.